Immune Pharma (NASDAQ: IMNP) gained pre-market after filing a joint patent on oral use of anti-eotaxin monoclonal antibodies with Hadasit ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE